Ad-hoc | 25 March 2015 07:00

Cytos Biotechnology AG: Novartis buys out CAD 106 license agreement for CHF 4 million

Cytos Biotechnology AG / Key word(s): Agreement

2015-03-25 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

Schlieren (Zurich), Switzerland, March 25, 2015 – Cytos Biotechnology Ltd (“Cytos”) today announced that Novartis has agreed to make a one-time payment of CHF 4 million to eliminate any further payment obligations under the Collaborative Research, Option and License Agreement for CAD106, which is under development by Novartis for the prevention of Alzheimer’s disease.

Cytos is planning to use the payment from Novartis to settle remaining payment obligations under the outstanding convertible loan notes, which remain subordinated.

The closing of the transaction with Novartis is expected to occur upon the conversion of the convertible bonds into Cytos shares in the second half of April 2015 and certain other closing conditions.

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

www.cytos.com

End of ad hoc announcement

+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=KAFNOJKSCK
Document title: Cytos_CAD106_150325

2015-03-25 News transmitted by EQS Schweiz AG. www.eqs.com – news archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

Language:	English
Company:	Cytos Biotechnology AG
	Wagistr. 25
	8952 Schlieren
	Switzerland
Phone:	+41 44 733 4747
Fax:	+41 44 733 4740
E-mail:	info@cytos.com
Internet:	www.cytos.com
ISIN:	CH0011025217, CH0029060735
Valor:	–
Listed:	Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market in Frankfurt ; SIX

End of News EQS Group News-Service

336909  2015-03-25